Laddar populära aktier...
Redeye leaves an initial comment following the Q3 report published by Magle this morning.
Redeye leaves a comment on the announced completion of the merger between Magle and Amniotics.
Redeye provides a research update following the Q2 report recently published by Magle.
Redeye leaves an initial comment following the Q2 report published by Magle this morning.
Redeye leaves a comment following Magle’s announcement of an acquisition of pK Biotech ApS and its subsidiary pK Chemicals A/S.
Redeye leaves a comment following the Magle Group’s announced merger with Amniotics yesterday.
Redeye leaves a short note following Magle’s announcement yesterday of the initial outcome of the public offer to acquire Amniotics and an e...
Redeye provides a research update following the Q1 report recently published by Magle.
Redeye leaves an initial comment following the Q1 report published by Magle this morning.
Redeye leaves a comment following the Magle Group’s announced public offer to acquire Amniotics earlier today.
Redeye leaves an initial comment following the Q4 report published by Magle this morning.
Redeye leaves a comment on the Q3 report published by Magle yesterday.
Redeye initiates coverage of Magle Chemoswed, a hybrid medtech/biotech company with a diverse array of revenue streams.
